Cash falls 67.6% to NZ$9.5M as revenue drops 8.6% on Medicare uncertainty

Operating revenue fell 8.6% to NZ$21.8M, with management attributing the decline to Medicare uncertainty and a reduced US sales force. Net loss after tax widened modestly to NZ$29.9M from NZ$29.5M, a 1.4% deterioration.

The segment picture shows the Commercial division remains the core, contributing NZ$21.9M in revenue and narrowing its segment loss to NZ$14.9M from NZ$17.3M. A Research segment reported NZ$4.8M in revenue with no prior-year comparable, contributing a NZ$15.0M segment loss and explaining much of the gap between operating revenue (NZ$21.8M) and total revenue (NZ$24.6M). Receivable days extended to 47.2 days from 38.9 days, a deterioration that warrants watching given the already-stressed cash position.

At NZ$9.5M closing cash with NZ$24.7M consumed in FY25 operations, the implied runway — assuming no improvement in burn — is well under six months. The second-half operating cash outflow was NZ$12.3M versus NZ$12.5M in the first half, showing no material deceleration in burn rate. This is not a quality-of-earnings question; it is a question of whether the business can continue without new capital.

Medicare uncertainty is suppressing the business's primary revenue driver. The 8.6% operating revenue decline and a 15.0% fall in US total test volumes (per management commentary) reflect a "holding pattern" in demand linked to US reimbursement uncertainty. Until Medicare coverage is resolved, the revenue base is structurally constrained, which means cost discipline alone cannot close the gap between revenues and operating spend.

Receivable days expanded sharply. Debtor days rose 8.3 days to 47.2 days, which on a shrinking revenue base means collections slowed even as volumes fell. For a business with NZ$9.5M in cash, any slippage in cash collection directly affects the ability to fund operations, so this movement is operationally significant rather than a routine working-capital fluctuation.

Management's stated framing — a "holding pattern" awaiting Medicare resolution — implies that FY25 results are not intended to represent a normalised run rate. The APAC contribution and sales force efficiency gains are cited as partial offsets, and US Tests/Sales FTE improved 6.4% in Q4 FY25 versus Q4 FY24, suggesting some operational recovery in the final quarter.

However, the absence of a clear Medicare resolution timeline means the path to cash-flow neutrality is undefined. The second-half revenue of NZ$10.9M being marginally below the first-half NZ$11.0M does not support a "sequential improvement" narrative, and the closing cash position means the company will need either a step-change in revenue or an external capital event in the near term.

Equity fell NZ$28.5M to NZ$26.1M over the year, driven by accumulated losses rather than asset write-downs. The Commercial segment improved its loss by NZ$2.3M, which is a genuine operating efficiency signal; however, this was offset by the Research segment's NZ$15.0M loss with no prior-year baseline for comparison, making the year-on-year total loss movement difficult to interpret as an improving trend.

Operating cash outflow narrowed slightly from NZ$25.8M to NZ$24.7M, but the FCF-to-NPAT ratio of 86.9% (versus 91.8% in FY24) means the cash drain is nearly as large as the reported accounting loss. There is no timing benefit, deferred liability, or balance-sheet offset moderating the cash consumption — what is being reported is close to the underlying economic burn.

This briefing cannot assess whether Pacific Edge's cash position is sufficient to reach a Medicare decision, nor can it evaluate the probability or timing of that regulatory outcome.